Integrating fluoroquinolones into the hospital formulary

Pharmacotherapy

Volumn 21, Issue 10 II SUPPL., 2001, Pages

  Bertino J S , Jr ^a  

^a BASSETT HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BETA LACTAM ANTIBIOTIC; CAFFEINE; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; CYCLOSPORIN; GATIFLOXACIN; GREPAFLOXACIN; IMMUNOSUPPRESSIVE AGENT; IRON; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; MULTIVITAMIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SUCRALFATE; SULTAMICILLIN; THEOPHYLLINE; TROVAFLOXACIN; UNINDEXED DRUG; WARFARIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BONE INFECTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEBRILE NEUTROPENIA; GASTROINTESTINAL INFECTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEART VENTRICLE ARRHYTHMIA; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; UROGENITAL TRACT INFECTION;

EID: 0034797437     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.16.273s.33996     Document Type: Review

References (85)

1. The quinolones: History and overview
2. Association between formulary strategies and hospital drug expenditures
3. Sequential antimicrobial therapy: A realistic approach to cost containment?
4. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin
5. Chemistry and mechanism of action of the quinolone antibacterials
6. Mechanism of action of and resistance to quinolones
7. Trends in bacterial resistance to fluoroquinolones
8. Bacterial resistance to fluoroquinolones: Mechanisms and patterns
9. High-level quinolone resistance in clinical isolates of Campylobacter jejuni
10. Antimicrobial resistance in Neisseria gonorrhoeae in the United States, 1988-1994: The emergence of decreased susceptibility to the fluoroquinolones
11. Gonococcal susceptibility to antimicrobials in Baltimore, 1988-1994
12. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus
13. Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S. aureus colonization
14. Epidemiology of ciprofloxacin resistance among patients with methicillin-resistant Staphylococcus aureus
15. Prevalence of ciprofloxacin resistance in multiresistant gram-negative intensive care unit isolates
16. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
17. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones in the United States
18. Risk factors associated with antimicrobial resistance among Streptococcus pneumoniae in the United States
19. Pharmacokinetics and pharmacodynamics of the fluoroquinolones
20. Use of quinolones in skin and skin structure (osteomyelitis) and other infections
21. Acute community-acquired sinusitis
22. Practice guidelines for the management of community-acquired pneumonia in adults
23. The role of the fluoroquinolones in respiratory infections
24. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the drug-resistant Streptococcus pneumoniae therapeutic working group
25. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases
26. Quinolones and tuberculosis
27. Quinolones for the treatment and prophylaxis of tuberculosis
28. Diagnosis and treatment of uncomplicated urinary tract infection
29. Treatment of pyelonephritis in adults
30. Practical approach to the management of prostatitis
31. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis
32. Single and multiple drug resistance among species of Enterobacteriaceae commonly found in urinary tract infections
33. Use of the quinolones for treatment and prophylaxis of bacterial gastrointestinal infections
34. Use of quinolones in surgery and obstetrics and gynecology
35. Peritonitis and other intra-abdominal infections
36. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis
37. Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts
38. Use of the quinolones in the prophylaxis and treatment of granulocytopenic immunocompromised cancer patients
39. A multicenter study of lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections
40. Comparative efficacy and safety of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection
41. Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis
42. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis
43. A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection
44. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin
45. Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women. . The minimum effective dose
46. Efficacy and tolerability of norfloxacin vs. ciprofloxacin in complicated urinary tract infection
47. A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections
48. Comparison of three-day temafloxacin with seven-day ciprofloxacin treatment of urinary tract infections in women
49. Multicenter study of single-dose and multiple-dose fleroxacin versus ciprofloxacin in the treatment of uncomplicated urinary tract infections
50. Fleroxacin versus ofloxacin in patients with complicated urinary tract infection: A controlled clinical study
51. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: Comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily
52. Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients
53. Safety and efficacy of temafloxacin versus ciprofloxacin in lower respiratory tract infections: A randomized, double-blind trial
54. Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections
55. Systemic antimicrobial therapy in skin and skin structure infections: Comparison of temafloxacin and ciprofloxacin
56. Comparison of ciprofloxacin, ofloxacin, and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies
57. Infection prophylaxis in neutropenic patients with acute leukemia - A randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin
58. GIMEMA infection program Prevention of bacterial infection in neutropenic patients with hematologic malignancies
59. Comparative efficacy and safety of single oral doses of sparfloxacin versus ciprofloxacin in the treatment of acute gonococcal urethritis in men
60. Randomized trial of trovafloxacin and ofloxacin for single-dose therapy of gonorrhea
61. Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections
62. A randomized, multinational study with sequential therapy comparing ciprofloxacin twice daily and ofloxacin once daily
63. A multicenter, double-blind, randomized study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections
64. Effectiveness of norfloxacin and ofloxacin for treatment of gonorrhoea and decrease of in vitro susceptibility to quinolones over time in Rwanda
65. Efficacy and safety of single oral dose sparfloxacin vs. ciprofloxacin in acute gonococcal urethritis in males
66. Comparing the efficacy of pefloxacin and ciprofloxacin in the treatment of acute uncomplicated gonococcal urethritis in males
67. Complicated urinary infection in spinal injury patients: Fleroxacin compared with ciprofloxacin
68. Fleroxacin 400 mg once daily versus ofloxacin 400 mg twice daily in skin and soft tissue infections
69. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy
70. Lomefloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections: A multicentre study
71. Ofloxacin compared with ciprofloxacin in the treatment of complicated lower urinary tract infections
72. A randomized study comparing low dose ciprofloxacin and ofloxacin in the treatment of lower respiratory tract infections
73. Antibacterial prophylaxis in granulocytopenic patients: A randomized study of ofloxacin versus norfloxacin
74. Rufloxacin in acute exacerbations of chronic bronchitis study group. 5-day rufloxacin treatment versus 7-day ciprofloxacin treatment in patients with acute exacerbations of chronic bronchitis
75. Open randomized comparison of ofloxacin and norfloxacin in the treatment of complicated urinary tract infections
76. Fluoroquinolone adverse effects and drug interactions
77. Fluoroquinolone toxicity profiles: A review focusing on newer agents
78. Implications of quinolone pharmacokinetic drug interactions